Investment analysts at Maxim Group started coverage on shares of Hemispherx BioPharma (NYSEAMERICAN:HEB) in a research note issued on Friday, The Fly reports. The firm set a “buy” rating on the specialty pharmaceutical company’s stock.
Separately, Ascendiant Capital Markets set a $44.00 price objective on shares of Hemispherx BioPharma and gave the stock a “buy” rating in a report on Friday, May 17th.
Shares of HEB opened at $5.35 on Friday. Hemispherx BioPharma has a fifty-two week low of $4.01 and a fifty-two week high of $14.96.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last released its quarterly earnings results on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) earnings per share (EPS) for the quarter.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.